Abstract
A global analysis of the impact of non-pharmaceutical interventions (NPIs) on the dynamics of the spread of the COVID-19 indicates that these can be classified using the stringency index proposed by the Oxford COVID-19 Government Response Tracker (OxCGRT) team. The world average for the coefficient that linearises the level of transmission with respect to the OxCGRT stringency index is αs = 0.01±0.0017 (95% C.I.). The corresponding South African coefficient is αs = 0.0078 ± 0.00036 (95% C.I.), compatible with the world average. Here, we implement the stringency index for the recently announced 5-tier regulatory alert system. Predictions are made for the spread of the virus for each alert level. Assuming constant rates of recovery and mortality, it is essential to increase αs. For the system to remain sub-critical, the rate with which αs increases should outpace that of the decrease of the stringency index. Monitoring of αs becomes essential to controlling the post-lockdown phase. Data from the Gauteng province obtained in May 2020 has been used to re-calibrate the model, where αs was found increase by 20% with respect to the period before lockdown. Predictions for the province are made in this light.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding received from the South African government through the Department of Science and Innovation, the University of Witwaterstrand and the IEEE. No funding came from third parties or commercial organisations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available on the South Africa Covid-19 Monitoring site: https://www.covid19sa.org/
